The Great Debates in Solid Tumors was held on September 13–14, 2025. The event recognized that oncology is not one-size-fits-all and featured three distinct education tracks—gastrointestinal, women’s, and lung cancers—each tailored to the complexities of solid tumor care.
Participants had exclusive access to a distinguished faculty presenting the latest clinical data and evolving standards of care. Attendees explored sessions across all tracks, engaged in debates and case-based discussions to deepen understanding of evidence-based approaches, and networked with colleagues committed to advancing patient outcomes. The event offered a valuable opportunity to connect, learn, and lead in solid tumor care.
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, Shared about This Event on Social Media:
Debating about Controversies in the Management of Lung Cancer:
“For this young girl who was once afraid of speaking in public (not to mention in English as a second language) to be asked to participate in Great Debates debating some of the best thoracic oncologist around, Corey Langer and Luis Raez, about controversies in the management of lung cancer is a dream.
It was also fun.”
Debating with Two of the Best Thoracic Oncologists I Know
“Ask me how it went on Monday. I’m debating two of the best thoracic oncologists I know and respect this weekend Great Debates in Miami.
Round 1 against: Luis E. Raez on CTLA-4 in Lung Cancer- The Time is Now.
Round 2 against: Corey Langer on Second line therapies for SCLC are for Marathon runners not all patients.”
Julia Rotow on 1L EGFR options coming out of WCLC25
“Julia Rotow gives her take on 1L EGFR options coming out of WCLC25 FLAURA2 presentation weighting in survival advantage (Quantity time) vs Quality of time (osi monotherapy).”
Coral Olazagasti wins debate of chemoIO vs IO alone combination
“Coral Olazagasti brings in the Benito Antonio reference and wins debate of chemoIO vs IO alone combination against Corey Langer.”
Still smiling after debating Luis Raez on IO monotherapy
“Still smiling after debating Luis Raez on IO monotherapy vs combination CTLA4/PDL1
Although I lost -due to a ‘sampling error’, -we both agreed that high risk tumors PDL1 neg, STK11, KEAP1, KRAS can benefit from CTLA4 therapy upfront).”
“So great to see Beth Eaby, nurse practicioner extraordinaire (who I trained with) moderating panel with Stephen Chun and Eshan Patel on 2nd line options in NSCLC, including TTFields and RT for oligoprogression- for whom and when is this appropriate?”
Surgery vs ChemoRT for locally advanced (N2) NSCLC
“Surgery vs ChemoRT for locally advanced (N2) NSCLC:
Round 1: Dr Jamie Chaft argues for Surgery with Neoadjuvant vs Perioperative ChemoIO. Reviewing Aegean trial with high N2 population, good surgical outcomes and pCR/PFS.”
Importance of multiD tumor discussions
“Drew Moghanaki discusses importance of multiD tumor discussions and radOnc consults for pts with Stage III NSCLC.
(Image courtesy of ChatGPT – AI inspired hybrid virtual and in person multiD discussions).”
More from Estela Rodriguez on OncoDaily.